Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Mitsunori Hino
Efficacy of Triple Antiemetic Therapy (Palonosetron, Dexamethasone, Aprepitant) for Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Carboplatin-Based, Moderately Emetogenic Chemotherapy.
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Related publications
Ramosetron Versus Palonosetron in Combination With Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
Cancer Research and Treatment
Cancer Research
Oncology
Efficacy of the Combination Use of Aprepitant and Palonosetron for Improving Nausea in Various Moderately Emetogenic Chemotherapy Regimens
BMC pharmacology & toxicology
Medicine
Pharmacology
Pharmacoeconomic Analysis of Using Aprepitant Plus Standard Antiemetic Therapy for Prevention of Nausea and Vomiting Associated With Highly and Moderately Emetogenic Cancer Chemotherapy in Russia
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Real-World Effectiveness of Palonosetron-Based Antiemetic Regimens: Preventing Chemotherapy-Induced Nausea and Vomiting
Journal of Comparative Effectiveness Research
Health Policy
Incidence of Chemotherapy-Induced Nausea and Vomiting With Moderately Emetogenic Chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) Study
Supportive Care in Cancer
Oncology
Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: Approval and Efficacy
Cancer Management and Research
Oncology
Antiemetics for Chemotherapy-Induced Nausea and Vomiting Occurring Despite Prophylactic Antiemetic Therapy
Journal of Palliative Medicine
Medicine
Anesthesiology
Pain Medicine
Nursing
Effects of Serum Sodium Concentrations on Nausea and Vomiting After Moderately Emetogenic Chemotherapy
Yakugaku Zasshi
Pharmacology
Pharmaceutical Science
Preventing Chemotherapy-Induced Nausea and Vomiting With Netupitant/Palonosetron, the First Fixed Combination Antiemetic: Current and Future Perspective
Future Oncology
Medicine
Cancer Research
Oncology
